Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

Study identifier:NIS-RSI-SYM-2006/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open-label non-interventional evaluation of efficacy of Symbicort® forte Turbuhaler 320/9 µg (budesonide / formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (budesonide / formoterol)in functional status improvement of patients with chronic obstructive pulmonary disease (COPD)

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

743

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Feb 2007

Primary Completion Date: 01 Sept 2007

Study Completion Date: 01 Sept 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1074&filename=CSR-NIS-RSI-SYM-2006-1.pdf
Download
CSR-NIS-RSI-SYM-2006-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZenec Slovenia Clinical Study Information

+38615135623

meta.jeras@astrazeneca.com

Investigators

Principal Investigator

Matjaz Flezar

Golnik Hospital